ArticleScientific reports2026
Metrnl ameliorates ulcerative colitis by inhibiting NLRP3 inflammasome activation via ASC.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Ulcerative colitis (UC) is characterized by the dysregulation of inflammatory pathways, leading to extensive tissue damage and chronic inflammation. NLRP3 inflammasome promotes inflammatory cytokine maturation and pyroptosis. Meteorin-like protein (Metrnl) has anti-inflammatory effects; however, its specific mechanisms in regulating these pathways remain unclear. This study investigated the effect of Metrnl on UC via regulation of the NLRP3 inflammasome through regulation of its key component, apoptosis-associated speck-like protein containing CARD (ASC). NCM460 and FHC cells were treated with TNF-α to establish a cell validation model. Cells with Metrnl interference or overexpression were intervened with three inflammasome activators (ATP, nigericin, or alum), and a caspase-1 inhibitor (belnacasan). The inflammatory factor levels, ASC mRNA and protein expressions, pyroptosis-related proteins, and inflammasome were detected. Interactions between ASC, Metrnl and inflammasome were determined by protein immunoprecipitation. UC models were constructed using wild-type and Metrnl knockout mice. Histopathological changes and differences in pyroptosis-related protein and inflammasome expressions were examined. Metrnl expression was significantly decreased in colitis, and the inflammatory factors IL-1β and LDH expressions increased at the cellular and animal levels, promoting ASC expression and pyroptosis, and activating the inflammasome. Metrnl interference accelerated inflammation and pyroptosis, which were reversed by Metrnl overexpression. Interactive relationships between Metrnl and ASC were noted. Metrnl may mediate ASC protein expression, and reduce IL-1β expression and pyroptosis in colon epithelial cells through the inhibition of ASC-NLRP3 binding. In vivo studies with DSS-induced colitis models confirmed the significance of these findings. After Metrnl knockout, the colon of normal mice was shorter, and Metrnl-/- UC mice showed more severe colon tissue damage, reduced goblet cells, increased inflammation, and accumulation of pyroptosis protein expression, indicating that Metrnl knockout increases susceptibility to UC. Metrnl interferes with key inflammatory signaling pathways in UC by inhibiting the interaction between ASC and NLRP3, suggesting its potential in UC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.